Overall Survival Results Reinforce Osimertinib as Standard of Care for EGFRm Stage IB-IIIA NSCLC

Updated phase 3 trial data provide practice-changing findings.

Related Keywords

New Haven ,Connecticut ,United States ,Kanagawa ,Fukushima ,Japan ,Yokohama ,Taiwan ,American ,Roys Herbst , ,Kanagawa Cancer Center ,American Society Of Clinical Oncology ,World Health Organization ,Japan The National Cancer Center Hospital ,Astrazeneca ,Yale Cancer Center ,Yale School Of Medicine ,Clinical Oncology ,Yale School ,National Cancer Center Hospital East ,National Cheng Kung University ,Tainan City ,